209 related articles for article (PubMed ID: 25315362)
61. Time-Course of Depression Improvement With Ketamine Adjunction in Electroconvulsive Therapy.
Romeo B; Choucha W; Fossati P; Rotge JY
J ECT; 2016 Jun; 32(2):80-1. PubMed ID: 26766630
[No Abstract] [Full Text] [Related]
62. Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine.
Lundin NB; Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Brutsche NE; Machado-Vieira R; Zarate CA
Pharmacopsychiatry; 2014 Jul; 47(4-5):141-4. PubMed ID: 24955551
[TBL] [Abstract][Full Text] [Related]
63. Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression.
Guo W; Machado-Vieira R; Mathew S; Murrough JW; Charney DS; Grunebaum M; Oquendo MA; Kadriu B; Akula N; Henter I; Yuan P; Merikangas K; Drevets W; Furey M; Mann JJ; McMahon FJ; Zarate CA; Shugart YY
Transl Psychiatry; 2018 Dec; 8(1):280. PubMed ID: 30552317
[TBL] [Abstract][Full Text] [Related]
64. Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.
Miller OH; Moran JT; Hall BJ
Neuropharmacology; 2016 Jan; 100():17-26. PubMed ID: 26211972
[TBL] [Abstract][Full Text] [Related]
65. Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.
Moaddel R; Shardell M; Khadeer M; Lovett J; Kadriu B; Ravichandran S; Morris PJ; Yuan P; Thomas CJ; Gould TD; Ferrucci L; Zarate CA
Psychopharmacology (Berl); 2018 Oct; 235(10):3017-3030. PubMed ID: 30116859
[TBL] [Abstract][Full Text] [Related]
66. Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression.
Romeo B; Choucha W; Fossati P; Rotge JY
Psychiatry Res; 2015 Dec; 230(2):682-8. PubMed ID: 26548981
[TBL] [Abstract][Full Text] [Related]
67. Is Ketamine the Future Clozapine for Depression? A Case Series and Literature Review on Maintenance Ketamine in Treatment-resistant Depression With Suicidal Behavior.
Chan LF; Eu CL; Soh SY; Maniam T; Shahidii Kadir Z; Chong BTW; Loo JL; Sharip S; Wong VCW; Loo TH; Ng YP; Kahn DA
J Psychiatr Pract; 2018 Jul; 24(4):279-291. PubMed ID: 30427812
[TBL] [Abstract][Full Text] [Related]
68. Ketamine for depression.
Jelen LA; Stone JM
Int Rev Psychiatry; 2021 May; 33(3):207-228. PubMed ID: 33569971
[TBL] [Abstract][Full Text] [Related]
69. Ketamine: Future Treatment For Unresponsive Depression?
Frere M; Tepper J
Ir Med J; 2016 Sep; 109(8):453. PubMed ID: 28124853
[TBL] [Abstract][Full Text] [Related]
70. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Newport DJ; Carpenter LL; McDonald WM; Potash JB; Tohen M; Nemeroff CB;
Am J Psychiatry; 2015 Oct; 172(10):950-66. PubMed ID: 26423481
[TBL] [Abstract][Full Text] [Related]
71. The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder.
McIntyre RS; Lipsitz O; Rodrigues NB; Lee Y; Cha DS; Vinberg M; Lin K; Malhi GS; Subramaniapillai M; Kratiuk K; Fagiolini A; Gill H; Nasri F; Mansur RB; Suppes T; Ho R; Rosenblat JD
Bipolar Disord; 2020 Dec; 22(8):831-840. PubMed ID: 32406161
[TBL] [Abstract][Full Text] [Related]
72. Intravenous Ketamine as an Effective and Safe Treatment in a Suicidal Patient With Cancer Who Was Nil Per Os.
Rajagukguk S; Lee T
Psychosomatics; 2020; 61(4):371-374. PubMed ID: 31739996
[No Abstract] [Full Text] [Related]
73. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
[TBL] [Abstract][Full Text] [Related]
74. Ketamine for the treatment of depression: what about the addictive potential?
Hillemacher T; Bleich S; Demling J; Kornhuber J
Aust N Z J Psychiatry; 2007 Sep; 41(9):772-3. PubMed ID: 17896416
[No Abstract] [Full Text] [Related]
75. Clinical predictors of ketamine response in treatment-resistant major depression.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Guevara S; Machado-Vieira R; Richards EM; Brutsche NE; Nolan NM; Zarate CA
J Clin Psychiatry; 2014 May; 75(5):e417-23. PubMed ID: 24922494
[TBL] [Abstract][Full Text] [Related]
76. The promise of ketamine for treatment-resistant depression: current evidence and future directions.
DeWilde KE; Levitch CF; Murrough JW; Mathew SJ; Iosifescu DV
Ann N Y Acad Sci; 2015 May; 1345(1):47-58. PubMed ID: 25649308
[TBL] [Abstract][Full Text] [Related]
77. Toward specific ways to combine ketamine and psychotherapy in treating depression.
Hasler G
CNS Spectr; 2020 Jun; 25(3):445-447. PubMed ID: 31213212
[TBL] [Abstract][Full Text] [Related]
78. A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders.
Kim S; Rush BS; Rice TR
Eur Child Adolesc Psychiatry; 2021 Oct; 30(10):1485-1501. PubMed ID: 32385697
[TBL] [Abstract][Full Text] [Related]
79. The Concurrent Treatment With Intravenous Ketamine and an Irreversible Monoamine Oxidase Inhibitor for Treatment-Resistant Depression Without Hypertensive Crises.
Wang JCC; Swainson J
J Clin Psychopharmacol; 2020; 40(5):515-517. PubMed ID: 32740556
[No Abstract] [Full Text] [Related]
80. Beneficial pre-ECT ketamine infusion in a patient with treatment-resistant depression.
Sultan R; Riva-Posse P; Garlow SJ; Schwartz AC
Psychosomatics; 2014; 55(4):396-399. PubMed ID: 24735865
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
